Regulus Therap (RGLS) Misses Q2 EPS by 10c

Regulus Therap (NASDAQ: RGLS) reported Q2 EPS of ($0.29), $0.10 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $3.19 million.

For earnings history and earnings-related data on Regulus Therap (RGLS) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Vail Resorts taps bankers for potential activist defense, Semafor reports
• HCB shareholders approve Independent Bank's acquisition deal